ABVX Abivax SA

ABIVAX : Publication du nombre d’actions composant le capital social et du nombre total de droits de vote

PARIS--(BUSINESS WIRE)--

Regulatory News:

ABIVAX (Paris:ABVX) :

Date  

Nombre

d’actions

  Nombre total de droits de vote
30/09/2016   9 702 089   Nombre de droits de vote théoriques(1) :   16 513 089
     
Nombre de droits de vote exerçables(2) :   16 354 589
         

(1) Le nombre de droits de vote théoriques (ou droits de vote « bruts »), sert de base de calcul pour les franchissements de seuils. Conformément à l’article 223-11 du Règlement Général de l’AMF, ce nombre est calculé sur la base de l’ensemble des actions auxquelles sont attachés des droits de vote, y compris les actions privés de droit de vote.

(2) Le nombre de droits de vote exerçables (ou droits de vote « nets ») est calculé en ne tenant pas compte des actions privées de droit de vote. Il est communiqué pour la bonne information du public, conformément à la recommandation de l’AMF du 17 juillet 2007.

ABIVAX est une société innovante de biotechnologie qui cible le système immunitaire pour éliminer des maladies virales. ABIVAX dispose de trois plateformes technologiques : une plateforme « anti-virale », une plateforme « immunostimulants » et une plateforme « anticorps polyclonaux ». Son produit le plus avancé, ABX464, est une nouvelle molécule prometteuse contre le VIH/SIDA, administrée par voie orale, à l’épreuve des résistances développées par le virus. ABIVAX développe également plusieurs candidats médicaments contre des virus additionnels et un candidat immunostimulants, dont plusieurs sont susceptibles d’entrer en phase de développement clinique dans les 18 prochains mois (Chikungunya, Ebola, Dengue, etc.). ABIVAX est cotée sur le compartiment B d’Euronext à Paris (ISIN : FR0012333284 – Mnémo : ABVX).

Plus d'informations sur : www.abivax.com

Suivez-nous sur Twitter @ABIVAX_

ABIVAX (Euronext Paris : FR0012333284 – ABVX),

Société anonyme à Conseil d’Administration au capital de 96 968,89€.

Siège social : 5, rue de la Baume, 75008 Paris

RCS : Paris B 799 363 718

FR
10/10/2016

Underlying

ABVXAbivax SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Abivax SA

 PRESS RELEASE
Free
ABVX ABIVAX SA

Abivax Announces Full Exercise of Underwriters’ Option to Purchase Add...

Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M) Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M) PARIS, France, July 25, 2025 – 08:00 a.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic i...

July 25, 2025 1 EN
 PRESS RELEASE
Free
ABVX ABIVAX SA

Abivax Announces Pricing of $650M (€554M) Public Offering of American ...

Abivax Announces Pricing of $650M (€554M) Public Offering of American Depositary Shares Abivax Announces Pricing of $650M (€554M) Public Offering of American Depositary Shares PARIS, France, July 24, 2025 – 2:30 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, today announces the pricing of its previously announced underwritten public offering ...

July 24, 2025 1 EN
 PRESS RELEASE
Free
ABVX ABIVAX SA

Abivax announces trading resumption of its ordinary shares on Euronext...

Abivax announces trading resumption of its ordinary shares on Euronext Paris Abivax announces trading resumption of its ordinary shares on Euronext Paris PARIS, France, July 24, 2025 – 02:30 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, announced the trading resumption of its ordinary shares on the regulated market of Euronext Paris as from ...

July 24, 2025 1 EN
 PRESS RELEASE
Free
ABVX ABIVAX SA

Abivax announces temporary trading halt of its ordinary shares on Euro...

Abivax announces temporary trading halt of its ordinary shares on Euronext Paris Abivax announces temporary trading halt of its ordinary shares on Euronext Paris PARIS, France, July 24, 2025 – 07:30 a.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, announced today that trading of its ordinary shares on the regulated market of Euronext Paris (“Eu...

July 24, 2025 1 EN
 PRESS RELEASE
Free
ABVX ABIVAX SA

Abivax Announces Launch of Public Offering

Abivax Announces Launch of Public Offering Abivax Announces Launch of Public Offering PARIS, France, July 23, 2025 – 10:15 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, announced today the launch of an approximately $400 million underwritten public offering (representing approximately €340 million) consisting of a public offering of its Amer...

July 23, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch